Phase
Condition
Mood Disorders
Psychosis
Tourette's Syndrome
Treatment
N/AClinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Subjects who are able to provide written informed consent. If the Institutional ReviewBoard (IRB) requires consent by a legally acceptable representative in addition to thesubject, all required consents must be obtained prior to any protocol-requiredprocedure.
Male and female subjects 18 to 65 years of age, inclusive
Current diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual ofMental Disorders (DSM-IV-TR) criteria and a history of the illness for at least 1 year (12 months)
Subjects who in the investigator's judgment would benefit from extended treatment witha long-acting injectable formulation
Subjects who have at least 1 inpatient psychiatric hospitalization in the 2 years (24months) prior to screening, but have been managed as outpatients for the 4 weeks priorentering the study
Subjects must have been on oral antipsychotic treatment for the full 7 months prior tothe screening phase Subjects who have shown response to previous antipsychotictreatment.
Subjects who understand the nature of the trial and are able to follow the protocolrequirements.
Exclusion
Exclusion Criteria:
Prisoners or subjects who are compulsorily detained (involuntarily incarcerated), orhave been incarcerated in the past 7 months for any reason must not be enrolled intothis trial.
Subjects who may require potent CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers duringthe trial.
Any subject who requires or may need any other antipsychotic medications during thecourse of the trial, other than allowed rescue medication.
Subjects who are known to be allergic, intolerant, or unresponsive to prior treatmentwith aripiprazole or other quinolinones.
Subjects with a history of hypersensitivity to antipsychotic agents.
Subjects deemed intolerant of receiving injectable treatment.
Subjects who have received electroconvulsive therapy within the last 7 months prior toscreening.
Subjects with a history of neuroleptic malignant syndrome or clinically significanttardive dyskinesia as assessed by the investigator.
Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, includingschizoaffective disorder, major depressive disorder, bipolar disorder, delirium,dementia, amnestic or other cognitive disorders. Also, subjects with borderline,paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
Subjects requiring hospitalization for any psychiatric reason during the 4 weeks priorto signing the Informed Consent Form (ICF) or during the screening period.
Subjects without at least 1 inpatient psychiatric hospitalization in the last 2 years (24 months) prior to screening.
Subjects who have met DSM-IV-TR criteria for any significant substance use disorderwithin 3 months prior to screening.
Subjects who are considered treatment-resistant to antipsychotic medication other thanclozapine.
Treatment with long-acting injectable antipsychotics in which the last dose was within 7 months prior to screening.
Subjects who have not been treated with oral antipsychotics for 7 months prior toscreening.
Subjects who have a significant risk of committing suicide
Subjects who have a history or evidence of a medical condition that would expose themto an undue risk of a significant adverse event or interfere with assessments ofsafety or efficacy during the course of the trial
Sexually active males and females who will not commit to utilizing birth controlduring the trial and for up to 180 days following the trial.
Abnormal laboratory or physical examination results indicating a condition which mayinterfere with the results of the study or pose a safety risk to the subject.
Subjects who have previously enrolled in an aripiprazole IM depot clinical study orwho have participated in any clinical trial with an investigational agent within thepast 30 days.
Study Design
Study Description
Connect with a study center
Brugge, 8310
BelgiumSite Not Available
Bruxelles, 1160
BelgiumSite Not Available
Kortenberg, 3070
BelgiumSite Not Available
empty
Liège, 4000
BelgiumSite Not Available
Liège, 4000
BelgiumSite Not Available
empty
Bourgas, 8000
BulgariaSite Not Available
empty
Kazanlak, 6100
BulgariaSite Not Available
Lovech, 5500
BulgariaSite Not Available
Novi Iskar, 1282
BulgariaSite Not Available
Pazardjik, 4400
BulgariaSite Not Available
empty
Pleven, 5800
BulgariaSite Not Available
empty
Plovdiv, 4000
BulgariaSite Not Available
empty
Sofia, 1632
BulgariaSite Not Available
empty
Tsarev brod, 9747
BulgariaSite Not Available
Tzerova Koria, 5047
BulgariaSite Not Available
empty
Varna, 9000
BulgariaSite Not Available
empty
Calgary, Alberta T2N 2T9
CanadaSite Not Available
Penticton, British Columbia V2A 4M4
CanadaSite Not Available
empty
Vancouver, British Columbia V6A3G3
CanadaSite Not Available
empty
Victoria, British Columbia V8R 4Z3
CanadaSite Not Available
empty
Halifax, Nova Scotia B3H 2E2
CanadaSite Not Available
empty
Brampton, Ontario L6T0G1
CanadaSite Not Available
Chatham, Ontario N7M 5L9
CanadaSite Not Available
empty
Oshawa, Ontario L1G 2B9
CanadaSite Not Available
empty
Toronto, Ontario M5T 1R8
CanadaSite Not Available
empty
Montreal, Quebec H3A1A1
CanadaSite Not Available
empty
Blois cedex, Centre 41016
FranceSite Not Available
empty
Montpellier, Herault 34295
FranceSite Not Available
empty
La Rochelle, Poitou-Charentes 17022
FranceSite Not Available
empty
Brumath Cedex, 67173
FranceSite Not Available
empty
Clermont Ferrand, 63000
FranceSite Not Available
empty
Dijon, 21000
FranceSite Not Available
empty
Dole, 39100
FranceSite Not Available
empty
Henin Beaumont Cedex, 62251
FranceSite Not Available
empty
Jonzac, 17503
FranceSite Not Available
empty
Limoges, 87025
FranceSite Not Available
empty
Marseille, 13005
FranceSite Not Available
empty
Nice, 06002 Cedex 1
FranceSite Not Available
empty
Romans Sur Isere, 26100
FranceSite Not Available
empty
Strasbourg Cedex, 67091
FranceSite Not Available
empty
Toulon, 83000
FranceSite Not Available
empty
Uzes, 30700
FranceSite Not Available
empty
Siegen, NRW 57072
GermanySite Not Available
empty
Achim, Niedersachsen 28832
GermanySite Not Available
empty
Berlin, 14050
GermanySite Not Available
empty
Bielefeld, 33647
GermanySite Not Available
empty
Bochum, 44892
GermanySite Not Available
empty
Greifswald, 17489
GermanySite Not Available
empty
Hattingen, 45525
GermanySite Not Available
empty
Homburg/Saar, 66421
GermanySite Not Available
empty
Mannheim, 68159
GermanySite Not Available
empty
Muenchen, 81675
GermanySite Not Available
empty
Ostfildern, 73760
GermanySite Not Available
empty
Tuebingen, 72076
GermanySite Not Available
empty
Wiesbaden, 65199
GermanySite Not Available
empty
Cagliari, Sardinia 09127
ItalySite Not Available
empty
Pisa, Tuscany 56100
ItalySite Not Available
empty
Andria, 70031
ItalySite Not Available
empty
Bari, 70124
ItalySite Not Available
empty
Brescia, 25123
ItalySite Not Available
empty
Catania, 95123
ItalySite Not Available
empty
Catanzaro, 88100
ItalySite Not Available
empty
Giulianova, 64021
ItalySite Not Available
empty
L'Aquila, 67100
ItalySite Not Available
empty
Lecce, 73100
ItalySite Not Available
empty
Milano, 20142
ItalySite Not Available
empty
Monza, 20052
ItalySite Not Available
empty
Orbassano, 10043
ItalySite Not Available
empty
Palermo, 90127
ItalySite Not Available
empty
Parma, 43121
ItalySite Not Available
empty
Roma, 137
ItalySite Not Available
empty
Sassari, 07100
ItalySite Not Available
empty
Udine, 33100
ItalySite Not Available
empty
Voghera, 27058
ItalySite Not Available
empty
Goyangshi, Kyeonggi-do 410-719
Korea, Republic ofSite Not Available
empty
Busan, 612-862
Korea, Republic ofSite Not Available
empty
Daejeon, 301-721
Korea, Republic ofSite Not Available
empty
Incheon, 400-711
Korea, Republic ofSite Not Available
empty
Jeonju-si, 561-712
Korea, Republic ofSite Not Available
empty
Seoul, 152-703
Korea, Republic ofSite Not Available
empty
Tuszyn, Lodzkie 95-080
PolandSite Not Available
empty
Bialystok, 15-464
PolandSite Not Available
empty
Choroszcz, 16-070
PolandSite Not Available
empty
Gdansk, 80-546
PolandSite Not Available
empty
Gdynia, 81-361
PolandSite Not Available
empty
Lodz, 91-229
PolandSite Not Available
empty
Lublin, 20-109
PolandSite Not Available
empty
Piekary Slaskie, 41-940
PolandSite Not Available
empty
Barcelona, 8025
SpainSite Not Available
empty
Coslada, 28822
SpainSite Not Available
empty
El Palmar, 30120
SpainSite Not Available
empty
Elche, 3293
SpainSite Not Available
empty
Gijón, 33211
SpainSite Not Available
empty
L'Hospitalet de Llobregat, 8907
SpainSite Not Available
empty
Madrid, 28032
SpainSite Not Available
empty
Majadahonda, 28222
SpainSite Not Available
empty
Málaga, 29004
SpainSite Not Available
empty
Málaga, 29004
SpainSite Not Available
empty
Sabadell, 8208
SpainSite Not Available
empty
Torrevieja, 3180
SpainSite Not Available
empty
Zamora, 49021
SpainSite Not Available
empty
Kaohsiung, 802
TaiwanSite Not Available
empty
Keelung, 204
TaiwanSite Not Available
empty
Taichung, 407
TaiwanSite Not Available
empty
Tainan, 704
TaiwanSite Not Available
empty
Taoyuan County, 333
TaiwanSite Not Available
empty
Xin-Yi District, Taipei, 110
TaiwanSite Not Available
empty
Bury St Edmunds, Suffolk IP33 2QZ
United KingdomSite Not Available
empty
Hull, Yorkshire HD6 7RX
United KingdomSite Not Available
empty
London, E1 4DG
United KingdomSite Not Available
empty
Fayetteville, Arkansas 72703
United StatesSite Not Available
empty
Los Angeles, California
United StatesSite Not Available
empty
Oceanside, California 92056
United StatesSite Not Available
empty
San Diego, California 92121
United StatesSite Not Available
empty
Miami, Florida 33144
United StatesSite Not Available
empty
Bloomfield Hills, Michigan 48302
United StatesSite Not Available
empty
Buffalo, New York 14215
United StatesSite Not Available
empty
Oklahoma City, Oklahoma
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.